# Efficacy and Safety of Liraglutide in Type 2 Diabetes With Lower Extremity Arterial Disease

Study · id `cardio:ct-nct04146155` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04146155](<https://clinicaltrials.gov/study/NCT04146155>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04146155

Browse, organ or system: Blood vessels; Metabolism  
Browse, condition area: Coronary and vascular disease; Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 200 participants.

## Technical summary

Registry record NCT04146155. Randomized; single masking; primary purpose treatment. Start 2020-05-01 (actual); primary completion 2021-12-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 200 participants (planned count; ClinicalTrials.gov record NCT04146155, source copy `cardio:ctgov-nct04146155-2021-07-07`, retrieved 2026-10-26)
- Started: 2020-05-01 (actual) (ClinicalTrials.gov record NCT04146155, source copy `cardio:ctgov-nct04146155-2021-07-07`, retrieved 2026-10-26)
- Primary completion: 2021-12-31 (anticipated) (ClinicalTrials.gov record NCT04146155, source copy `cardio:ctgov-nct04146155-2021-07-07`, retrieved 2026-10-26)
- Completion: 2021-12-31 (anticipated) (ClinicalTrials.gov record NCT04146155, source copy `cardio:ctgov-nct04146155-2021-07-07`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT04146155, source copy `cardio:ctgov-nct04146155-2021-07-07`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04146155-2021-07-07`, retrieved 2026-10-26)

## The registry's words

- Brief title: Efficacy and Safety of Liraglutide in Type 2 Diabetes With Lower Extremity Arterial Disease
- Condition: Type 2 Diabetes
- Condition: Peripheral Vascular Disorder Due to Diabetes Mellitus
- Intervention (Drug): Liraglutide+standard-of-care treatment
- Intervention (Other): standard-of-care treatment
- Lead sponsor: Second Affiliated Hospital, Zhejiang University, School of Medicine
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Peripheral artery disease (`cardio:peripheral-artery-disease`)
- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry lists this organization as the lead sponsor: Second Affiliated Hospital, Zhejiang University, School of Medicine (`cardio:org-second-affiliated-hospital-zhejiang-university-school-of-bfd3ac`)

## Provenance

Content hash: 4d522b83fcc72063bab2f95da05edab548f24070a0153f55baa009e73ea4b421
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
